Home>>Signaling Pathways>> Apoptosis>> RIP kinase>>Nec-4

Nec-4

Catalog No.GC33620

Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 (RIP1) inhibitor, with an IC50 of 2.6 μM, Ki of 0.46 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Nec-4 Chemical Structure

Cas No.: 1041644-43-2

Size Price Stock Qty
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 (RIP1) inhibitor, with an IC50 of 2.6 μM, Ki of 0.46 μM.

Nec-4 (compound 9) is a slightly better competitor than 7 with a lower Ki value that is similar to R-3. Nec-4 is again a slightly better competitor than Rac-3 with Ki and IC50 values comparable to 7 (Nec-4: IC50=2.6±0.1 μM, Ki=0.46±0.05 μM; 7: IC50=10.7±1.8 μM, Ki=4.5±0.9 μM). Overall, all three compounds cross-compete with each other but Nec-4 is able to more effectively displace both 20 and 26 in comparison to the parent compounds Rac-3 and 7, respectively. This suggests that Nec-4 binding likely significantly overlaps with both the Nec-1 and the Nec-3 binding sites.

[1]. Maki JL, et al. Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1. Anal Biochem. 2012 Aug 15;427(2):164-74.

Reviews

Review for Nec-4

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nec-4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.